Over 11,000 Bottles of Blood Pressure Medications Recalled for 'Failed Dissolution Specifications'

The U.S. Food and Drug Administration has recalled more than 11,000 bottles of a blood pressure medication due to failed dissolution specifications. The agency announced on June 5 that Chlorthalidone Tablets, USP, 25 mg, manufactured by Inventia Healthcare Limited in India and distributed by Rising Pharma Holdings, Inc., in East Brunswick, New Jersey, are affected. The recall covers batch RISA24001 (100 bottles) and batch RISB24002 (1,000 bottles), with a total of 11,460 bottles involved and an expiration date of April 2027. This action follows a separate recall in May of Olmesartan medoxomil and amlodipine products, affecting 15,696 bottles with an October 31, 2027 expiration. Regulators have not yet specified health risks from consuming the recalled tablets, but the recall underscores ongoing quality-control vigilance for hypertension medicines. Consumers who possess the recalled Chlorthalidone should consult their healthcare provider about alternatives and pursue a replacement or refund through the retailer. The recall comes as part of a broader wave of blood pressure drug recalls this spring.